What is Bio-Thera Solutions?
Headquartered in Guangzhou, China, Bio-Thera Solutions operates as a sophisticated biopharmaceutical enterprise dedicated to the discovery and commercialization of next-generation antibody drugs. The company addresses a diverse spectrum of therapeutic areas, including oncology, autoimmune disorders, and cardiovascular conditions. By maintaining a rigorous quality management system that aligns with international GMP standards across the United States, the European Union, and China, Bio-Thera has successfully transitioned from a research-focused entity to a commercial-stage powerhouse. Its portfolio, which notably includes the first domestically produced adalimumab injection, serves as a testament to its technical prowess and regulatory compliance in highly competitive global markets.
The company's strategic focus on addressing urgent clinical needs has enabled it to establish a significant footprint in the pharmaceutical sector. Through a combination of internal innovation and strategic partnerships, Bio-Thera is actively expanding its market presence, particularly within Southeast Asia, where it seeks to leverage its manufacturing capabilities to meet rising demand for high-quality, affordable biologic therapies.
How much funding has Bio-Thera Solutions raised?
Bio-Thera Solutions has raised a total of $241M across 1 funding round:
Stock Offering
$241M
Stock Issuance/Offering (2020): $241M, investors not publicly disclosed
Key Investors in Bio-Thera Solutions
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Bio-Thera Solutions?
Looking ahead, the infusion of capital will likely be directed toward scaling manufacturing capacity and broadening the reach of its clinical-stage assets. As the company continues to navigate the complexities of the global biopharmaceutical market, its focus will remain on optimizing its antibody drug platform to address unmet medical needs. The strategic deployment of these funds is expected to bolster the company's competitive advantage, facilitating deeper penetration into international markets and supporting the long-term sustainability of its research initiatives. Investors and industry observers will be monitoring the firm's ability to translate this financial backing into tangible clinical outcomes and expanded market share in the coming fiscal periods.
See full Bio-Thera Solutions company page
